Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease., Shimizu Masanori;Suzuki Kunihiro;Kato Kanako;Jojima Teruo;Iijima Toshie;Murohisa Toshimitsu;Iijima Makoto;Takekawa Hidehiro;Usui Isao;Hiraishi Hideyuki;Aso Yoshimasa, Diabetes, obesity & metabolism, 21(2), 285-292, 2019